糖尿病性肝病诊治进展

doi:10.3969/j.issn.1672-5069.2018.04.050

摘要/Abstract

摘要： 糖尿病性肝病是指由糖尿病所致的肝脏疾病,主要包括非酒精性脂肪性肝病和糖源性肝病两种。在糖尿病患者中糖尿病性肝病患病率高,危害大。目前,对于该病的认识相对匮乏。本文重点介绍糖尿病性肝病的临床和病理学特点、发病机制和治疗进展。

Abstract: Diabetic hepatopathy (DH) is a complications of diabetes, most commonly arised from non-alcoholic fatty liver disease and glycogenic hepatopathy. DH has a high morbidity and always leads to serious clinical consequences. However, the disease has been neglected to date. In this review, we summarized the findings regarding the clinical and pathological features, mechanisms and therapeutic strategies of the disease.

Key words: Diabetic hepatopathy, Non-alcoholic fatty liver disease, Glycogenic hepatopathy

杨彦综述, 王煊审校. 糖尿病性肝病诊治进展[J]. 实用肝脏病杂志, 2018, 21(4): 653-656.

Yang Yan, Wang Xuan. Diagnosis and treatment of patients with diabetic hepatopathy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 653-656.

参考文献

[1] Xu Y,Wang L,He J,et al.Prevalence and control of diabetes in Chinese adults. JAMA,2013,310(9):948-959.
[2] Tolman KG,Fonseca V,Dalpiaz A,et al.Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care,2007,30(3):734-743.
[3] Porepa L,Ray JG,Sanchez-Romeu P,et al.Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ,2010,182(11):E526-531.
[4] de Marco R,Locatelli F,Zoppini G,et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care,1999,22(5):756-761.
[5] Angulo P.Nonalcoholic fatty liver disease. N Engl J Med,2002,346(16):1221-1231.
[6] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南(2010年1月修订). 中华内科杂志,2010,49(3):275-278.
[7] Masarone M,Rosato V,Aglitti A,et al.Liver biopsy in type 2 diabetes mellitus:Steatohepatitis represents the sole feature of liver damage. PLoS One,2017,12(6):e0178473.
[8] European Association for the Study of the L,European Association for the Study of D European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts,2016,9(2):65-90.
[9] Reeder SB,Cruite I,Hamilton G,et al.Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging,2011,34(4):729-749.
[10] 韦敏怡,冼苏,秦映芬,等. 糖尿病患者肝脏病变的病理研究. 中国糖尿病杂志,2005,13(6):454-455.
[11] Wan Y,Garner J,Wu N,et al.Role of stem cells during diabetic liver injury. J Cell Mol Med,2016,20(2):195-203.
[12] Takamatsu S,Noguchi N,Kudoh A,et al.Influence of risk factors for metabolic syndrome and non-alcoholic fatty liver disease on the progression and prognosis of hepatocellular carcinoma. Hepatogastroenterology,2008,55(82-83):609-614.
[13] Raza H,Prabu SK, John A,et al.Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int J Mol Sci,2011,12(5):3133-3147.
[14] Unal D,Aksak S,Halici Z,et al.Effects of diabetes mellitus on the rat liver during the postmenopausal period. J Mol Histol,2011,42(3):273-287.
[15] Grigorov I,Bogojevic D,Jovanovic S,et al.Hepatoprotective effects of melatonin against pronecrotic cellular events in streptozotocin-induced diabetic rats. J Physiol Biochem,2014,70(2):441-450.
[16] Ortiz-Avila O,Gallegos-Corona MA,Sanchez-Briones LA,et al.Protective effects of dietary avocado oil on impaired electron transport chain function and exacerbated oxidative stress in liver mitochondria from diabetic rats. J Bioenerg Biomembr,2015,47(4):337-353.
[17] Canbay A,Friedman S,Gores GJ.Apoptosis:the nexus of liver injury and fibrosis. Hepatology,2004, 39(2):273-278.
[18] Zhang Q,Li Y,Liang T,et al.ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice. Int J Biol Sci,2015,11(5):559-568.
[19] Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L,et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology,2015,149(2):367-378, e365; quiz e314-365.
[20] Esposito K,Marfella R,Ciotola M,et al.Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA,2004,292(12):1440-1446.
[21] Misciagna G,Del Pilar Diaz M,Caramia DV,et al. Effect of a low glycemic index mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial. J Nutr Health Aging,2017,21(4):404-412.
[22] Donadon V,Balbi M,Mas MD,et al.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease. Liver Int,2010,30(5):750-758.
[23] 信丰智,范建高. 欧洲非酒精性脂肪性肝病诊疗指南简介. 实用肝脏病杂志,2016,4(19):519-520.
[24] Mazzotti A,Caletti MT,Marchignoli F,et al.Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease Dig Liver Dis,2017,49(3):235-240.
[25] Gentile S,Turco S,Guarino G,et al.Effect of treatment with acarbose and insulin in patients with non-insulin-dependent diabetes mellitus associated with non-alcoholic liver cirrhosis. Diabetes Obes Metab,2001,3(1):33-40.
[26] Gentile S,Guarino G,Romano M,et al.A randomized controlled trial of acarbose in hepatic encephalopathy. Clin Gastroenterol Hepatol,2005,3(2):184-191.
[27] Armstrong MJ,Gaunt P,Aithal GP,et al.Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN):a multicentre,double-blind,randomised,placebo-controlled phase 2 study. Lancet,2016,387(10019):679-690.
[28] Torbenson M,Chen YY,Brunt E,et al.Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol,2006,30(4):508-513.
[29] Ikarashi Y,Kogiso T,Hashimoto E,et al.Four cases of type 1 diabetes mellitus showing sharp serum transaminase increases and hepatomegaly due to glycogenic hepatopathy. Hepatol Res,2017,47(3):E201-E209.
[30] Mukewar S,Sharma A,Lackore KA,et al.Clinical,biochemical,and histopathology features of patients with glycogenic hepatopathy. Clin Gastroenterol Hepatol,2017,15(6):927-933.
[31] Von Sengbusch A,Tannapfel A,Klein HH,et al.Hepatomegaly and elevated transaminases in a 24-year-old with type I diabetes mellitus. Internist (Berl),2010,51(1):84-87.
[32] Saadi T.Glycogenic hepatopathy:a rare disease that can appear and resolve rapidly in parallel with glycemic control. Isr Med Assoc J,2012,14(4):269-270.
[33] Van den Brand M,Elving LD,Drenth JP,et al. Glycogenic hepatopathy:a rare cause of elevated serum transaminases in diabetes mellitus. Neth J Med,2009,67(11):394-396.
[34] Ferrer JC,Favre C,Gomis RR,et al.Control of glycogen deposition. FEBS Lett,2003,546(1):127-132.
[35] Parmar N,Atiq M,Austin L,et al.Glycogenic hepatopathy: thinking outside the box. Case Rep Gastroenterol,2015,9(2):221-226.